Laboratory research, digital technologies and regulatory authorities are working hand in hand to bring therapeutic cancer vaccines to market.
Cancer research has come a long way in a short space of time. As immunotherapy and gene therapy pioneer Dr Stephen Rosenberg has pointed out, the traditional tools available to treat cancer – surgery, chemotherapy and radiotherapy – now have a fourth pillar. immunotherapy.
Advances in immunotherapy treatments, starting with early steps such as interleukin-2, and more recently the US FDA-approved immunotherapies that target critical immunoregulatory molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death receptor 1 (PD-1) represent significant advances and are now standard of care treatments for advanced melanoma.
Check out the rest of this feature here
